Re My comment on Valuation of Cvac
Refer Prima Presentation Dated 27th Feb 2015 slide 40
Feb. 2014. Valeant (world’s No. 34 pharma company) acquired Provenge for 400 Million.
Provenge® 2014 US$304m net product revenue, up 7% -4Q14: Cash-flow break-even
Look at the figures Provane was / is a market leader and did great for a Yearly revenue of 304 Million at break-even so efficiency at production, distribution and marketing would make it profitable year 2 and so on.
So, given the newness of Cvac but with better results.. there is promise both in development and One off License sale
PreMarket22May_Nasdaq, page-8
-
- There are more pages in this discussion • 12 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
32.0¢ |
Change
-0.035(9.86%) |
Mkt cap ! $479.3M | |||
| Open | High | Low | Value | Volume |
| 34.0¢ | 34.5¢ | 31.5¢ | $1.248M | 3.750M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 17 | 123110 | 31.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 32.0¢ | 332777 | 17 |
View Market Depth
| Last trade - 12.31pm 15/07/2024 (20 minute delay) ? |
| IMM (ASX) Chart |